Investing
Medivation Jumps on Prostate Cancer Drug Test (MDVN, DNDN, JNJ)
Published:
Last Updated:
Shares of development-stage drug maker Medivation Inc. have risen sharply today as the company said that its MDV3100 late-stage prostate cancer drug for patients who have failed chemotherapy extends life expectancy by 4.8 months. The drug does not challenge Dendreon Inc.’s (NASDAQ: DNDN) Provenge prostate cancer treatment, which attacks early-stage prostate cancer, but will compete with Johnson & Johnson’s (NYSE: JNJ) Zytiga late-stage drug.
Medivation’s shares are up nearly 24% at $68.59 after posting a new 52-week high of $68.81 earlier. See today’s story on Dendreon and Provenge here.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
